XML 26 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statement of Changes in Shareholders’ Equity (capital Deficiency) - USD ($)
$ in Thousands
Ordinary shares
Additional paid-in capital
Accumulated deficit
Total
Balance at Dec. 31, 2017 $ 41 $ 7,814 $ (16,129) $ (8,274)
Balance (in Shares) at Dec. 31, 2017 20,257,434      
Issuance of ordinary shares $ 17 3,667 3,684
Issuance of ordinary shares (in Shares) 1,666,774      
Share-based compensation 115 115
Net loss for the year (1,909) (1,909)
Balance at Dec. 31, 2018 $ 58 11,596 (18,038) (6,384)
Balance (in Shares) at Dec. 31, 2018 21,924,208      
Issuance of ordinary shares and warrants, net of issuance costs $ 16 14,022 14,038
Issuance of ordinary shares and warrants, net of issuance costs (in Shares) 4,762,656      
Issuance of ordinary shares to employees and non-employees upon exercise of warrants $ 1 136 137
Issuance of ordinary shares to employees and non-employees upon exercise of warrants (in Shares) 454,166      
Issuance of ordinary shares to investors upon exercise of warrants [1] 25 25
Issuance of ordinary shares to investors upon exercise of warrants (in Shares) 9,050      
Share-based compensation 16,245 16,245
Additional consideration with respect to an assets purchase agreement, see note 1c and note 6 (10,276) (10,276)
Net loss for the year (22,563) (22,563)
Balance at Dec. 31, 2019 $ 75 31,748 (40,601) (8,778)
Balance (in Shares) at Dec. 31, 2019 27,150,080      
Issuance of ordinary shares and warrants, net of issuance costs $ 14 70,999 71,013
Issuance of ordinary shares and warrants, net of issuance costs (in Shares) 4,624,500      
Initial public offering of ordinary shares, net of offering costs $ 31 169,136 169,167
Initial public offering of ordinary shares, net of offering costs (in Shares) 10,555,556      
Issuance of ordinary shares to employees and non-employees upon exercise of warrants $ 3 497 500
Issuance of ordinary shares to employees and non-employees upon exercise of warrants (in Shares) 997,863      
Issuance of ordinary shares to investors upon exercise of warrants $ 5 125 130
Issuance of ordinary shares to investors upon exercise of warrants (in Shares) 1,662,929      
Share-based compensation 24,781 24,781
Conversion of related party liability to shareholders’ equity, see note 8a $ 3 17,745 17,748
Conversion of related party liability to shareholders’ equity, see note 8a (in Shares) 1,109,245      
Net loss for the year (43,815) (43,815)
Balance at Dec. 31, 2020 $ 131 $ 315,031 $ (84,416) $ 230,746
Balance (in Shares) at Dec. 31, 2020 46,100,173      
[1] Less than 1 thousand US dollars.